New classes of drugs to treat type 2 diabetes are continually being developed and marketed. The FDA has issued guidance to the pharmaceutical industry that newer hypoglycemic agents should not be associated with unacceptable increases in cardiovascular risk. To date, five trials have assessed specific cardiovascular endpoints for these newer agents. Empagliflozin and liraglutide have been found to improve cardiovascular outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.JAA.0000530303.23280.6c | DOI Listing |
Publication Analysis
Top Keywords
classes drugs
8
cardiovascular
4
cardiovascular effects
4
effects newer
4
newer classes
4
drugs type
4
type diabetes?
4
diabetes? classes
4
drugs treat
4
treat type
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!